BENGALURU (Reuters) – Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.
(Reporting by Anuron Kumar Mitra in Bengaluru)
